Cite
HARVARD Citation
Alan, O. et al. (2020). How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature. Journal of oncology pharmacy practice. pp. 1011-1018. [Online].